Description
Azimilide 2HCl, a class III antiarrhythmic compound, blocks the Kv7.1 and Kv11.1 patassium channels. It also inhibits Na+/Ca2+ exchanger in vitro.
Product information
CAS Number: 149888-94-8
Molecular Weight: 530.88
Formula: C23H30Cl3N5O3
Synonym:
Azimilide Dihydrochloride
NE-10064 Dihydrochloride
Chemical Name: 2,4-Imidazolidinedione, 1-(((5-(4-chlorophenyl)-2-furanyl)methylene)amino)-3-(4-(4-methyl-1-piperazinyl)butyl)-, dihydrochloride
Smiles: Cl.Cl.CN1CCN(CCCCN2C(=O)N(CC2=O)/N=C/C2=CC=C(O2)C2C=CC(Cl)=CC=2)CC1
InChiKey: HHPSICLSNHCSNZ-BYEGLACWSA-N
InChi: InChI=1S/C23H28ClN5O3.2ClH/c1-26-12-14-27(15-13-26)10-2-3-11-28-22(30)17-29(23(28)31)25-16-20-8-9-21(32-20)18-4-6-19(24)7-5-18;;/h4-9,16H,2-3,10-15,17H2,1H3;2*1H/b25-16+;;
Technical Data
Appearance: Solid Power
Purity: ≥98% (or refer to the Certificate of Analysis)
Solubility: H2O : 2.22 mg/mL (4.18 mM; Need ultrasonic) DMSO : 1.67 mg/mL (3.15 mM; Need ultrasonic)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥12 months if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined
HS Tariff Code: 382200
How to use
In Vivo:
Azimilide has shown excellent efficacy (>85%) in suppressing supraventricular arrhythmias in a variety of dog models. It also suppressed complex ventricular arrhythmias in infarcted dogs and, in a sudden death cardiac model, decreased mortality[1].
References:
- Karam R , Marcello S , Brooks R R , et al. Azimilide Dihydrochloride, a Novel Antiarrhythmic Agent[J]. American Journal of Cardiology, 1998, 81(6-supp-S1):40-46.
- Abrol R , Page R L . Azimilide dihydrochloride: a new class III anti-arrhythmic agent[J]. Expert Opinion on Investigational Drugs, 2000, 9(11):2705-2715.
- Busch AE, et al. Blockade of HERG channels by the class III antiarrhythmic azimilide: mode of action. Br J Pharmacol. 1998 Jan;123(1):23-30.
- Yao JA, et al. Azimilide (NE-10064) can prolong or shorten the action potential duration in canine ventricular myocytes: dependence on blockade of K, Ca, and Na channels. J Cardiovasc Electrophysiol. 1997 Feb;8(2):184-98.
- Fermini B, et al. Use-dependent effects of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization: block of delayed rectifier potassium and L-type calcium currents. J Cardiovasc Pharmacol. 1995 Aug;26(2):259-71.
- Black SC, et al. Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug. J Cardiovasc Pharmacol. 1993 Dec;22(6):810-8.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.